Evogene (NASDAQ:EVGN) was given a new price target of $12.00 by Lake Street Capital

Evogene (NASDAQ:EVGN – Free Report) reduced their price objective on Lake Street Capital from $30.00 to $12.00 in a research report on Friday morning, Benzinga reports. Lake Street Capital currently has a buy rating on the biotechnology company’s stock.

Separately, StockNews.com began coverage on Evogene in a research note on Thursday. They have issued a sell rating on the company.

Check out our latest report on Evogene

Evogene stock up 9.3%

Shares of EVGN opened at $3.88 on Friday. The stock has a market cap of $159.92 million, a P/E ratio of -8.43 and a beta of 1.40. Evogene has a 52-week low of $3.45 and a 52-week high of $10.40. The firm has a 50-day simple moving average of $5.35 and a 200-day simple moving average of $6.79.

Evogene (NASDAQ:EVGN – Get Your Free Report ) last released its quarterly earnings data on Thursday, August 22nd. The biotechnology company reported ($1.06) EPS for the quarter. The firm had revenue of $0.91 million for the quarter. Evogene had a negative return on equity of 70.96% and a negative net margin of 233.66%.

Institutional trading of Evogene

An institutional investor recently raised its position in Evogene shares. BNP Paribas Financial Markets boosted its stake in Evogene Ltd. (NASDAQ:EVGN – Free Report) by 30.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 91,400 shares of the biotechnology company’s stock after acquiring an additional 21,500 shares during the period. BNP Paribas Financial Markets owned 0.22% of Evogene worth $69,000 as of its most recent SEC filing. Institutional investors own 10.40% of the company’s shares.

About Evogene

(Get a free report)

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life science-based industries, including human health and agriculture, using its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health and Industrial Applications.

Featured stories

Get news and reviews for Evogene Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Evogene and related companies with MarketBeat.com’s FREE daily email newsletter.